Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The Future of Pancreatic Cancer

July 20th 2016

Immunotherapy in Pancreatic Cancer

July 20th 2016

Novel Agents in Pancreatic Cancer

July 20th 2016

PARP Inhibitors in Pancreatic Cancer

July 20th 2016

Third-Line Therapy for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer: Updated NCCN Guidelines

July 20th 2016

The NAPOLI-1 Trial in Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Therapeutic Sequencing

July 20th 2016

Therapy for Locally Advanced Pancreatic Cancer

July 20th 2016

Adjuvant Therapy in Locally Advanced Pancreatic Cancer

July 20th 2016

Practical Considerations in Chemotherapy Regimens for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Upfront Therapy

July 20th 2016

Continued Challenges in Pancreatic Cancer Research

July 20th 2016

Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

July 20th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Possible Biomarker Could Determine Risk of Colon Cancer Recurrence

July 15th 2016

A liquid biopsy test of circulating tumor DNA for residual disease may be able to determine the risk of recurrence for patients with stage II colon cancer beyond radiologic tests and clinicopathological risk features.

Dr. Heinemann on Surrogate Markers Beyond PFS in Patients With CRC

July 14th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses surrogate markers aside from progression-free survival (PFS) in studying patients with colorectal cancer (CRC).

Immunotherapy Potential Continues to Grow in Gastric Cancers

July 14th 2016

Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.

Dr. Sharma on Results of SIRFLOX Study for CRC

July 14th 2016

Navesh K. Sharma, DO, PhD, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab for patients with liver metastatic colorectal cancer (CRC).

A Closer Look at Tumor Location Analyses in Colon Cancer

July 14th 2016

Tumor Locations in CRC

July 14th 2016